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Abstract— Aims: The study aimed to evaluate psychometrically a Danish translation of the Short Alcohol Withdrawal Scale (SAWS)
in an outpatient setting in patients with Alcohol Dependence (AD) and Alcohol Withdrawal Symptoms/Syndrome (AWS). Methods:
One hundred and twenty-two patients with AD and AWS ﬁlled in a 10-item rating scale to describe their symptoms with four gradua-
tions on ﬁve physical and ﬁve psychological items. The question of dimensionality of the construct was addressed in three diﬀerent
ways. First, a scree plot was constructed based on the polychoric correlations between items. Second, promax factor loadings were
calculated for a two-factor model. These two steps were based on exploratory factor analysis. Third, speciﬁc violations such as local
dependence and diﬀerential item functioning were investigated under the one-factor model in a conﬁrmatory factor analysis. Results:
The scree plot supported one or two dimensions while the promax rotations gave little support for a two-factor model. The conﬁrmatory
analysis also supported a one-factor model. Conclusion: The decomposition of the polychoric correlation matrix into eigenvalues and
vectors suggested that there was most likely one factor underlying the 10 items in the SAWS. This was conﬁrmed by a conﬁrmative
factor analysis with only one component when speciﬁc model violations such as local dependence and diﬀerential item ﬁndings were
investigated. The SAWS is easy to use.
INTRODUCTION
Previously Alcohol Withdrawal Syndrome (AWS) was one of
the cardinal diagnostic criteria for Alcohol Dependence (AD),
and in the present version of the international disease classiﬁ-
cation AWS is one of the six diagnostic criteria. AWS is one of
the most important barriers against seeking alcohol treatment
(Gossop et al., 2002). Adequate treatment of AWS is therefore
imperative for the patients’motivation for seeking treatment in
inpatient as well as outpatient treatment programmes. Further-
more, suﬃcient treatment of AWS will reduce the risk of
relapse and severity of future AWS (Becker, 1998; Malcolm
et al., 2000). A number of scales have been developed to mon-
itor the AWS in inpatient settings for example the Windsor
Clinic Alcohol Withdrawal Assessment Scale (Metcalfe et
al., 1995), the revised 10 item Clinical InstituteWithdrawal As-
sessment (CIWA-Ar) Scale (Nuss et al., 2004; Sullivan et al.,
1989), the revised 8-item Clinical Institute Withdrawal Assess-
ment (CIWA-AD) (Reoux et al. , 2006), the Alcohol
Withdrawal Symptom Checklist (Pittman et al., 2007) and
the AWS scale (Wetterling et al., 1997). Only the Short Alcohol
Withdrawal Scale (SAWS) has been used and validated in out-
patients (Gossop et al., 2002). Outpatient treatment for AWS is
widely used but no consensus exists regarding a standardized
monitoring of AWS (Saitz et al., 1997). Benzodiazepines are
the drugs of choice for the treatment of AWS (National Board
of Health, 2006), and at the Alcohol Unit, Hvidovre Hospital
chlordiazepoxide has been used for decades administered ac-
cording to a ﬁxed dosage schedule — tapering the dose to
zero over 8–10 days. No monitoring or systematic documenta-
tion of symptoms has been used unless the patient complained
of continuing clinical symptoms in spite of treatment compli-
ance. In that case, the dosage of AWS medication would be
changed. A ﬁxed dosage scheme suﬀers from the lack of indi-
vidualized treatment, lack of monitoring and documentation of
symptoms and a paternalistic view hampering the patients’mo-
tivation for continued adherence to treatment. Therefore, it is
important to implement a monitoring instrument in the treat-
ment of AWS in outpatient settings. The aim of the present
study was to validate the SAWS scale (Gossop et al., 2002)
in the context of a randomized controlled trial comparing ﬁxed




Consecutive outpatients suﬀering from AD and AWS were in-
cluded in the study and randomized to a ﬁxed-schedule
treatment or a symptom-triggered treatment with chlordiaz-
epoxide. All patients were evaluated by means of the
European Addiction Severity Index. Patients fulﬁlling Interna-
tional Classiﬁcation of Diseases 10th revision (ICD-10)
diagnostic criteria for AD and diagnostic criteria for AWS
were included if abstinence from alcohol had lasted for
<72 h prior to inclusion and they had ﬂuent Danish. Patients
were excluded from the study if they were allergic to chlordi-
azepoxide, used drugs with known interaction with
chlordiazepoxide, if they had been treated for AWS within
the last week or had a history of three or more attempts of
outpatient detoxiﬁcation within the last month. Furthermore,
patients were excluded if they had known severe psychiatric
illness including Wernicke/Korsakoﬀ syndrome, suicidal be-
haviour, severe cardiac or liver disease and type 1 diabetes.
Pregnant or breastfeeding women and fertile women without
safe contraception were excluded.
Finally, patients were excluded if breath alcohol concentra-
tion was >10 mg%.
Design
The patients were randomized into two groups: ﬁxed-schedule
or symptom-triggered medication. Randomization was per-
formed as block randomization by a statistician (KL) at The
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Research Centre at Hvidovre Hospital using the Randomiza-
tion System-Copenhagen Trial Unit 1.04. The randomization
was stratiﬁed according to SAWS score at baseline (score <12
or score >12). Sealed envelopes were delivered to the nurse by
a secretary instructed to hand out the envelope with the lowest
number from the block indicated by the nurse. Patients at-
tended the outpatient clinic daily preferably for 10 days. In
the ﬁxed-schedule group, 200 mg chlordiazepoxide was pre-
scribed as starting dose with daily tapering of the dose with
25 mg for patients with SAWS score ≥12 at baseline. For pa-
tients scoring SAWS <12 at baseline, the starting dose of
chlordiazepoxide was 80 mg with daily tapering of the dose
with 10 mg. Patients were instructed to take the medication as
prescribed and were oﬀered an extra dose if necessary.
In the symptom-triggered group, patients scoring ≥12 at
baseline were prescribed a maximum daily dose of chlordiaz-
epoxide of 300 mg for 10 days. For patients scoring SAWS
<12, the maximum daily dose was 120 mg for 10 days.
These patients also had the possibility of taking extra doses
if necessary.
All patients were instructed to bring back any unused ta-
blets. To support abstinence, patients in both arms were
oﬀered concurrent treatment with disulﬁram and/or acampro-
sate and controlled by breath alcohol levels.
SAWS
All patients ﬁlled in a rating scale (SAWS) with 10 items
(Table 1) — ﬁve physical and ﬁve psychological items.
Each item was scored 0 to 3 points retrospectively for the
last 24 h, where 0 denotes no symptoms and 3 denotes se-
vere symptoms. Patients were instructed to ﬁll in the SAWS
every day, preferably when they woke up. All patients ﬁlled
out the SAWS scale until they terminated treatment or 10
consecutive days after enrolment giving a total of 100 obser-
vations per patient. The SAWS scores were transferred to the
medical record by their nurse and time to SAWS <12. Treat-
ment should be continued for at least 5 days, and the cut-oﬀ
value of 12 was chosen after monitoring of AWS symptom
scores in a pilot study of 18 patients.
Statistical methods
The framework for the analysis is a factor analytical model
(Bollen, 1989). All measurements in all patients irrespective
of treatment group were included in the analysis. As the items
are ordered categorically, a threshold model is used assuming
an underlying continuous and normal distributed variable
(Muthén, 1984) for each of the items. All analyses are carried
out for all time points separately. The question of dimension-
ality of the construct is addressed in three diﬀerent ways.
First, a scree plot (Cattell, 1966) is shown based on the poly-
choric correlations between items. A scree plot is the plotting
of the eigenvalues of the correlation matrix in decreasing or-
der. Second, promax factor loadings are shown for the two-
factor model. These two steps are based on exploratory factor
analysis. Third, speciﬁc violations such as local dependence
(Chen et al., 1997) and diﬀerential item functioning (item bi-
as) (Holland et al., 1993) are investigated under the one-factor
model in a conﬁrmatory factor analysis. All estimates are
maximum likelihood estimates and all tests are likelihood ra-
tio tests. Analysis was carried out in Mplus, version 4
(Muthén et al., 2006) and R, version 2.4.0 (R core develop-
ment team, 2009).
Ethical approval
All participating patients gave informed consent according to
the Helsinki Declaration, and the project was approved by The
Danish National Committee on Biomedical Research Ethics
(ref. no. 01-063/03), The Danish Medicines Agency (ref.
no. 2612-2264) and Danish Data Protection Agency (ref.
no. 2003-41-2937).
RESULTS
One hundred and ﬁfty-three consecutive outpatients were ran-
domized. Most of the 31 patients dropped out because of
relapse before day 10. Thus, 122 patients participated in the
study (99 men and 23 women (symptom triggered n = 56,
ﬁxed schedule n = 66)) (Table 2). All patients were abstinent
for 10 days (receiving disulﬁram or documented by breath al-
cohol test).
Table 3 shows the mean severity score for each of the 10
items in the SAWS scale from day 1 to day 10. Initially, rest-
lessness, feeling miserable and sleep disturbance were those
items with highest severity scores.
As seen from Fig. 1, there was clearly one dominating fac-
tor. Using the Kaiser Guttman rule (to count the number of
eigenvalues larger than one), it seems reasonable to conclude
that there were at most two. The second largest eigenvalue is
1.35, 1.13, 0.99, 0.95, 1.06, 1.12, 1.07, 0.99, 1.09 and 1.01 for
the 10 days, respectively, yielding no decisive conclusion of
whether there are one or two underlying dimensions. Fig. 2
shows promax rotations of factor loadings from the explorato-
ry two-factor model for days 1, 4, 7 and 10. Days 2, 3, 5, 6,
Table 1. The Short Alcohol Withdrawal Scale (SAWS)











The patients ﬁll in the SAWS by ticking the appropriate boxes showing how
they have been feeling for each of the 10 symptoms in the previous 24 h. Each
item is scored on a 4-point scale: 0 = no symptoms, 1 = mild symptoms, 2 =
moderate symptoms and 3 = severe symptoms.The scores are summed up to
give a total score.
Table 2. Sex, age and other descriptive characteristics of the included patients
Median Men Women Total





Mean number of drinks (range)
19 17.5 21









8 and 9 days looked similar. Although it may seem that factor
loadings change over time, this is not the main point illustrat-
ed by the plots. Their most interesting feature is the lack of
evidence for a two-factor model.
The one-factor model was investigated by testing against
local dependence and diﬀerential item functioning with re-
spect to gender and age. There are 45 correlations between
pairs of items at each of the 10 days. Table 4 shows results
from the analysis of local dependence in Bonferroni-corrected
P-values for the largest modiﬁcation index at each of the
10 days. Although signiﬁcant local dependence was found
at days 5, 6 and 8, it is not immediately clear whether this
is due to multiple testing. However, investigating the consis-
tency of the ﬁndings over the 10 days sheds light on this issue;
Table 4 also shows which pairs have modiﬁcation indices
above 3.84 (95th percentile in the chi-square distribution with
one degree of freedom). Even though there is no distinct clus-
tering of the items in two groups, some pairs of items are
consistently closer correlated than others. Finally, the one-fac-
tor model was ﬁtted with additional residual correlation
between those two pairs of items, and — as to be expected
from Table 4 — this model provided an excellent ﬁt to the
data at all 10 days. No diﬀerential item functioning was found
with respect to gender and age.
DISCUSSION
Rating scales for AWS are helpful in prescribing the right
dose of medication, monitoring symptoms in order to identify
patients in risk of developing complications and for docu-
menting AWS treatment. Furthermore, the use of symptom-
triggered treatment schedules has been shown to be of beneﬁt
(McKay et al., 2004). However, few studies have validated
rating scales for AWS (Williams et al., 2001).
Instead of a factor analysis, we could have used a Rasch
model analysis but that model does not have the same con-
structivity on dimensionality as the factor analysis. The scree
plot suggested either one or two subscales in the SAWS
questionnaire, and the promax factor loadings from the
two-factor model were not indicative of there being two fac-
tors. A few violations of the one-factor model were found
when investigating the local dependence between the items
and no diﬀerential item functioning was detected. We did
not conﬁrm the ﬁnding of a two-component scale (Gossop
et al., 2002).
Were the 10 items driven by two latent variables, of which
some of the items load on one and the rest of the items load on
the other, then the factor loadings would cluster in those two
separate groups accordingly? As there is no such separation of
the items into two groups, the distribution of the factor load-
ings does not support a two-factor model. This being said,
there seems to be a slight though systematic change in the
loadings over the time so that if you were to group the items
into two, the grouping suggested by Gossop et al. (2002)
seems reasonable at the end of the observation period (days
7–10; days 8 and 9 not shown). However, this grouping does
not seem reasonable at the ﬁrst 6 days of the observation pe-
riod (only days 1 and 4 shown).
In particular, items 2 and 5 turn out to have a signiﬁcant re-
sidual correlation in 9 out of 10 days, while the correlation
between items 6 and 10 is signiﬁcant in 7 out of 10 days. It is
interesting that item 2 ‘feeling confused’ and item 5 ‘problems
with memory’ were strongly correlated because these items
represent symptoms of the AWS as well as side eﬀects to the
use of benzodiazepines. Secondly, item 6 ‘tremor/shakes’ and
item 10 ‘sweating’were correlated probably because symptoms
reﬂect reactions from the autonomic nervous systems.
We found all 10 items to be relevant and well understood
by clinicians and patients as well as the 24 hourly scoring was
Table 3. Mean severity score for each item of the SAWS score from day 1 to day 10. For the sum scores, standard deviations are shown in parentheses
Item Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10
1. Anxious 1.0 0.8 0.7 0.6 0.5 0.5 0.4 0.4 0.4 0.3
2. Feeling confused 0.8 0.9 0.8 0.7 0.8 0.7 0.7 0.5 0.5 0.4
3. Restless 2.2 1.8 1.6 1.4 1.2 1.1 1.0 0.9 0.7 0.6
4. Miserable 2.0 1.4 1.2 1.1 0.9 0.8 0.6 0.6 0.5 0.4
5. Problems with memory 0.9 0.8 0.8 0.8 0.7 0.7 0.7 0.6 0.5 0.5
6. Tremor (shakes) 1.8 1.3 1.0 0.8 0.7 0.6 0.5 0.4 0.3 0.3
7. Nausea 0.7 0.6 0.3 0.3 0.2 0.1 0.1 0.2 0.1 0.1
8. Heart pounding 1.1 0.7 0.5 0.4 0.3 0.3 0.3 0.2 0.1 0.1
9. Sleep disturbance 2.0 1.3 1.0 0.9 0.8 0.8 0.7 0.6 0.5 0.5
10. Sweating 1.9 1.4 1.0 0.7 0.6 0.5 0.4 0.3 0.3 0.3
Sum scores 14.9 (5.8) 11.1 (6.0) 9.1 (5.8) 7.7 (5.8) 6.8 (5.7) 6.3 (5.8) 6.3 (5.1) 4.6 (4.9) 4.0 (4.6) 3.6 (4.6)
Fig. 1. Scree plot based on the polychoric correlation matrix for each of the
ten days.
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well understood. Furthermore, inclusion of both somatic and
psychic items is clinically relevant and easy to use in daily
clinical practice. There is no reason why SAWS cannot be
used at a ‘present state’ measure or scoring with shorter inter-
vals or shorter monitoring periods as suggested by Gossop et
al. (2002). To our knowledge, a conﬁrmatory study of SAWS
has not been done before over a period of 10 days. Gossop et
al. (2002) used a 1–3 days monitoring period. Measuring and
monitoring AWS in an outpatient setting may assure suﬃcient
treatment to patients with AWS and at the same time making it
possible to monitor symptoms over time and document the
treatment. Because of the frequent measuring and treatment
according to the scoring, it may slow down the kindling eﬀect
on the brain according to other studies (Becker, 1998). Many
studies have given the patients’ involvement in their own de-
scription of AWS symptoms a less important role. Object
rating for AWS is in many rating scales the choice, though
it seems that patients are suﬀering due to lack of scoring fre-
quencies and new staﬀ. Some AWS symptoms are diﬃcult to
score and describe from object-rating scales (i.e. feeling rest-
less). Making the patients responsible for their own AWS
scoring as in self-rating and thereby responsible for their
own treatment will be a major challenge for the staﬀ and their
view on the patients suﬀering from AWS.
In conclusion, the decomposition of the polychoric correla-
tion matrix into eigenvalues and vectors suggested that there
was most likely one factor underlying the 10 items. This was
conﬁrmed by a conﬁrmative factor analysis with only one
component when speciﬁc model violations such as local de-
pendence and diﬀerential item ﬁndings were investigated. The
Fig. 2. Promax rotated factor loadings from a two-factor exploratory factor analysis for four of the ten days. The numbers plotted in each plot refers to the 10
factors analyzed.
Table 4. Local dependence between pairs of items
Day Pairs of items with modiﬁcation index (MI) >3.84
a
Max. MI P-valuec
1 1;2 2;5 5;7 10.098 0.067
2 2;5 3;5b 6;7b 6;9b 8.846 0.132
3 2;5 3;5b 8.425 0.167
4 2;5 6;10 8.948 0.125
5 6;7b 6;10 12.464 0.019
6 2;5 3;4 6;10 14.600 0.006
7 2;5 2;10b 6;10 7.364 0.299
8 2;5 6;10 7,8 10.856 0.044
9 2;5 6;10 9.906 0.074
10 2;5 6;10 4.837 1.000
aThe 95th percentile is 3.84 in the chi-square distribution with one degree of
freedom.
bThe residual correlation is negative.
cBonferroni-corrected P-values for each day.
Pairs that are signiﬁcant on 5% level are shown, as well as test statistics (Max
MI) and P-values for test of local dependence corrected for multiple testing.
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SAWS is easy to use. Further studies should focus on the use
of SAWS for individual prescription of drugs for the treatment
of AWS.
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